Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Molecular insights for the tumor suppressor role of SPOP in prostate cancer.

Created on 13 Sep 2026

Authors

Peiqiang Yan, Xutong Xue, Tao Hou, Jingchao Wang, Weiwei Jiang, Zhen Wang, Hiroyuki Inuzuka, Wenyi Wei

Published in

Biochimica et biophysica acta. Reviews on cancer. Volume 1881. Issue 2. Pages 189560. Epub Feb 16, 2026.

Abstract

Speckle-type POZ protein (SPOP) functions as a substrate adaptor within the cullin 3-based E3 ubiquitin ligase complex, playing an essential role in regulating diverse cellular processes by targeting specific proteins toward ubiquitination and proteasomal degradation. Aberrations in SPOP-driven proteolytic pathways have been implicated in the initiation and progression of prostate cancer. In this context, SPOP appears to function largely as a tumor suppressor by mediating the degradation of several oncogenic proteins such as AR, SRC3, CDC20, MYC, ERG, PD-L1, and BRD4. Mutations that impair SPOP function can result in the promotion of these substrates' oncogenic function, contributing to tumor initiation and progression. Hence, a deeper investigation into the molecular mechanisms of SPOP in prostate cancer will provide novel insights into its physiological function in oncogenesis and drug development. In this review, we summarize SPOP's tumor suppressor functions and structural features, upstream regulatory mechanisms, and SPOP-targeting therapeutic strategies in prostate cancer.

PMID:
41707797
Bibliographic data and abstract were imported from PubMed on 13 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement